The present invention relates to novel 1,3-diphenylpropane derivatives, pharmaceutical compositions containing them and their therapeutic use, especially in the field of human and animal health. The compounds of the present invention have endogenous PPAR agonist properties. Therefore, they are metabolic and / or inflammatory diseases associated with metabolic syndrome such as various forms of steatohepatitis, type 2 diabetes, various neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease and multiple sclerosis and in particular Of particular relevance to the treatment of peripheral and central diseases.本発明は、新規１,３－ジフェニルプロパン誘導体、それを含む医薬組成物および特にヒトおよび動物の健康の分野におけるその治療的使用に関する。本発明の化合物は内因性ＰＰＡＲアゴニスト特性を有する。それゆえに、それらはメタボリック症候群、例えば多様な形態の脂肪性肝炎、２型糖尿病、多様な神経変性障害、例えばアルツハイマー病、パーキンソン病および多発性硬化症と関連する代謝および／または炎症性疾患および特に末梢および中枢疾患の処置に特に関係する。
